Although the precise functions and mechanisms of action of CD99 in MDS and AML remain to be determined, these studies demonstrate that CD99 is an attractive candidate for targeting stem cells in lower-risk MDS as well as AML. Here, CD99 is linked to myelodysplastic syndrome.